Home
RGEN
RGEN News

Latest Repligen Corporation (RGEN) News on April 25, 2025

Will Repligen (RGEN) Beat Estimates Again in Its Next Earnings Report?

Zacks

a day ago

Will Repligen (RGEN) Beat Estimates Again in Its Next Earnings Report?

Earnings Preview: Guardant Health (GH) Q1 Earnings Expected to Decline

Zacks

2 days ago

Earnings Preview: Guardant Health (GH) Q1 Earnings Expected to Decline

Argus Research

2 days ago

RGEN: Rating decreased to a SELL

Repligen (RGEN) Reports Next Week: Wall Street Expects Earnings Growth

Zacks

3 days ago

Repligen (RGEN) Reports Next Week: Wall Street Expects Earnings Growth

Three Stocks That May Be Undervalued In April 2025

Simply Wall St.

8 days ago

Three Stocks That May Be Undervalued In April 2025

GMAB or RGEN: Which Is the Better Value Stock Right Now?

Zacks

9 days ago

GMAB or RGEN: Which Is the Better Value Stock Right Now?

Argus Research

9 days ago

RGEN: Raising target price to $133.00

Repligen to Report First Quarter 2025 Financial Results

GlobeNewswire

10 days ago

Repligen to Report First Quarter 2025 Financial Results

Repligen (RGEN): Buy, Sell, or Hold Post Q4 Earnings?

StockStory

15 days ago

Repligen (RGEN): Buy, Sell, or Hold Post Q4 Earnings?

Argus Research

16 days ago

RGEN: Lowering target price to $114.00

Repligen Appoints Jacob Johnson As Vice President Investor Relations

GlobeNewswire

17 days ago

Repligen Appoints Jacob Johnson As Vice President Investor Relations

MT Newswires

17 days ago

RBC Cuts Price Target on Repligen to $202 From $219, Keeps Outperform Rating

Repligen (RGEN) Moves 3.7% Higher: Will This Strength Last?

Zacks

17 days ago

Repligen (RGEN) Moves 3.7% Higher: Will This Strength Last?

Argus Research

23 days ago

RGEN: Lowering target price to $135.00

Winners And Losers Of Q4: IQVIA (NYSE:IQV) Vs The Rest Of The Drug Development Inputs & Services Stocks

StockStory

a month ago

Winners And Losers Of Q4: IQVIA (NYSE:IQV) Vs The Rest Of The Drug Development Inputs & Services Stocks

Argus Research

a month ago

RGEN: Lowering target price to $149.00

Is Repligen Corporation (RGEN) the Top Stock to Buy According to 12 West Capital Management?

Insider Monkey

a month ago

Is Repligen Corporation (RGEN) the Top Stock to Buy According to 12 West Capital Management?

Drug Development Inputs & Services Stocks Q4 In Review: Medpace (NASDAQ:MEDP) Vs Peers

StockStory

a month ago

Drug Development Inputs & Services Stocks Q4 In Review: Medpace (NASDAQ:MEDP) Vs Peers

Ascendis Pharma (ASND) Soars 10.4%: Is Further Upside Left in the Stock?

Zacks

a month ago

Ascendis Pharma (ASND) Soars 10.4%: Is Further Upside Left in the Stock?

MT Newswires

a month ago

Evercore ISI Initiates Repligen at In Line With $155 Price Target

Q4 Rundown: PacBio (NASDAQ:PACB) Vs Other Life Sciences Tools & Services Stocks

StockStory

a month ago

Q4 Rundown: PacBio (NASDAQ:PACB) Vs Other Life Sciences Tools & Services Stocks

Q4 Earnings Recap: Azenta (NASDAQ:AZTA) Tops Drug Development Inputs & Services Stocks

StockStory

a month ago

Q4 Earnings Recap: Azenta (NASDAQ:AZTA) Tops Drug Development Inputs & Services Stocks

A Look Back at Drug Development Inputs & Services Stocks’ Q4 Earnings: Repligen (NASDAQ:RGEN) Vs The Rest Of The Pack

StockStory

a month ago

A Look Back at Drug Development Inputs & Services Stocks’ Q4 Earnings: Repligen (NASDAQ:RGEN) Vs The Rest Of The Pack

Morningstar Research

a month ago

Analyst Report: Repligen Corporation

3 Small-Cap Stocks Skating on Thin Ice

StockStory

2 months ago

3 Small-Cap Stocks Skating on Thin Ice

Thomson Reuters StreetEvents

2 months ago

Q4 2024 908 Devices Inc. Earnings Call

Argus Research

2 months ago

RGEN: Lowering target price to $163.00

MT Newswires

2 months ago

Top Midday Gainers

908 Devices Strategic Shift: Desktop Sale To Repligen Optimizes Future Growth

Benzinga

2 months ago

908 Devices Strategic Shift: Desktop Sale To Repligen Optimizes Future Growth

MT Newswires

2 months ago

Repligen Buys 908 Devices' Desktop Portfolio for $70 Million

Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices

GlobeNewswire

2 months ago

Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices

Argus Research

2 months ago

RGEN: Raising target price to $170.00

Morningstar Research

2 months ago

Analyst Report: Repligen Corporation

Repligen's Q4 Earnings Beat Estimates, Revenues In Line

Zacks

2 months ago

Repligen's Q4 Earnings Beat Estimates, Revenues In Line

MT Newswires

2 months ago

RBC Raises Price Target on Repligen to $205 From $203, Keeps Outperform Rating

MT Newswires

2 months ago

Deutsche Bank Adjusts Repligen Price Target to $195 From $190, Maintains Buy Rating

Repligen Corp (RGEN) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

GuruFocus.com

2 months ago

Repligen Corp (RGEN) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

Thomson Reuters StreetEvents

2 months ago

Q4 2024 Repligen Corp Earnings Call

Morningstar Research

2 months ago

Analyst Report: Repligen Corporation

Repligen Q4 Earnings Momentum Highlights Market Growth, Issues Strong 2025 Outlook

Benzinga

2 months ago

Repligen Q4 Earnings Momentum Highlights Market Growth, Issues Strong 2025 Outlook

February 2025's US Stocks That May Be Trading Below Fair Value

Simply Wall St.

2 months ago

February 2025's US Stocks That May Be Trading Below Fair Value

What To Expect From Repligen Corp (RGEN) Q4 2024 Earnings

GuruFocus.com

2 months ago

What To Expect From Repligen Corp (RGEN) Q4 2024 Earnings

Repligen (RGEN) Beats Q4 Earnings Estimates

Zacks

2 months ago

Repligen (RGEN) Beats Q4 Earnings Estimates

Repligen (NASDAQ:RGEN) Posts Q4 Sales In Line With Estimates

StockStory

2 months ago

Repligen (NASDAQ:RGEN) Posts Q4 Sales In Line With Estimates

Associated Press Finance

2 months ago

Repligen: Q4 Earnings Snapshot

MT Newswires

2 months ago

Repligen Q4 Adjusted Earnings Decline, Revenue Increases -- Shares Up Pre-Bell

Repligen Reports Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire

2 months ago

Repligen Reports Fourth Quarter and Full Year 2024 Financial Results

Earnings To Watch: Repligen (RGEN) Reports Q4 Results Tomorrow

StockStory

2 months ago

Earnings To Watch: Repligen (RGEN) Reports Q4 Results Tomorrow

Repligen Corporation's (NASDAQ:RGEN) Intrinsic Value Is Potentially 80% Above Its Share Price

Simply Wall St.

2 months ago

Repligen Corporation's (NASDAQ:RGEN) Intrinsic Value Is Potentially 80% Above Its Share Price

Morningstar Research

2 months ago

Analyst Report: Repligen Corporation

3 Healthcare Stocks Skating on Thin Ice

StockStory

2 months ago

3 Healthcare Stocks Skating on Thin Ice

Repligen to Report Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire

2 months ago

Repligen to Report Fourth Quarter and Full Year 2024 Financial Results

MT Newswires

2 months ago

TD Cowen Initiates Repligen at Buy With $200 Price Target

Argus Research

3 months ago

RGEN: Rating increased to a HOLD

MT Newswires

3 months ago

RBC Trims Price Target on Repligen to $203 From $207, Keeps Outperform Rating

HRMY vs. RGEN: Which Stock Is the Better Value Option?

Zacks

3 months ago

HRMY vs. RGEN: Which Stock Is the Better Value Option?

Repligen (RGEN) Surges 3.7%: Is This an Indication of Further Gains?

Zacks

3 months ago

Repligen (RGEN) Surges 3.7%: Is This an Indication of Further Gains?

Argus Research

3 months ago

RGEN: Raising target price to $147.00

Argus Research

3 months ago

RGEN: Raising target price to $144.00

Argus Research

3 months ago

RGEN: Raising target price to $139.00

HRMY or RGEN: Which Is the Better Value Stock Right Now?

Zacks

3 months ago

HRMY or RGEN: Which Is the Better Value Stock Right Now?

Morningstar Research

3 months ago

Analyst Report: Repligen Corporation

3 US Stocks Including Advanced Energy Industries That May Be Priced Below Estimated Value

Simply Wall St.

4 months ago

3 US Stocks Including Advanced Energy Industries That May Be Priced Below Estimated Value

Repligen Corporation to Present at 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

4 months ago

Repligen Corporation to Present at 43rd Annual J.P. Morgan Healthcare Conference

Repligen Launches the CTech™ SoloVPE® PLUS System

GlobeNewswire

4 months ago

Repligen Launches the CTech™ SoloVPE® PLUS System

Argus Research

4 months ago

RGEN: Lowering target price to $131.00

Repligen Corporation (RGEN) Fell Along with Peers

Insider Monkey

4 months ago

Repligen Corporation (RGEN) Fell Along with Peers

Morningstar Research

4 months ago

Analyst Report: Repligen Corporation

Argus Research

4 months ago

RGEN: Raising target price to $140.00

Morningstar Research

4 months ago

Analyst Report: Repligen Corporation

BioLife Solutions Appoints Tony J. Hunt to its Board of Directors

PR Newswire

4 months ago

BioLife Solutions Appoints Tony J. Hunt to its Board of Directors

Repligen (RGEN) Up 3.2% Since Last Earnings Report: Can It Continue?

Zacks

4 months ago

Repligen (RGEN) Up 3.2% Since Last Earnings Report: Can It Continue?

Repligen Announces Publication of the Company’s 2023 Corporate Sustainability Report

GlobeNewswire

4 months ago

Repligen Announces Publication of the Company’s 2023 Corporate Sustainability Report

Argus Research

4 months ago

RGEN: Raising target price to $137.00

Several Factors Lifted Repligen Corporation (RGEN) in Q3

Insider Monkey

5 months ago

Several Factors Lifted Repligen Corporation (RGEN) in Q3

Repligen Launches Novel AVIPure® dsRNA Resin in OPUS® Pre-packed Columns

GlobeNewswire

5 months ago

Repligen Launches Novel AVIPure® dsRNA Resin in OPUS® Pre-packed Columns

MT Newswires

5 months ago

RBC Lifts Price Target on Repligen to $207 From $205, Keeps Outperform Rating

Argus Research

5 months ago

RGEN: Raising target price to $134.00

Argus Research

5 months ago

RGEN: Raising target price to $132.00

3 US Stocks Estimated To Be Trading At Discounts Up To 49.1%

Simply Wall St.

5 months ago

3 US Stocks Estimated To Be Trading At Discounts Up To 49.1%

MT Newswires

5 months ago

Repligen Insider Sold Shares Worth $3,386,439, According to a Recent SEC Filing

MT Newswires

5 months ago

Wolfe Research Initiates Repligen at Peer Perform

MT Newswires

5 months ago

UBS Adjusts Price Target on Repligen to $190 From $185, Keeps Buy Rating

Morningstar Research

5 months ago

Analyst Report: Repligen Corporation

Company News for Nov 13, 2024

Zacks

5 months ago

Company News for Nov 13, 2024

Thomson Reuters StreetEvents

5 months ago

Q3 2024 Repligen Corp Earnings Call

Repligen Corp (RGEN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

GuruFocus.com

5 months ago

Repligen Corp (RGEN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

Argus Research

5 months ago

RGEN: Raising target price to $134.00

Repligen Beats on Q3 Earnings & Sales, Narrows '24 Sales View

Zacks

5 months ago

Repligen Beats on Q3 Earnings & Sales, Narrows '24 Sales View

MT Newswires

5 months ago

Top Midday Gainers

Repligen Stock Soars 10% on Record Growth and Bold Moves

GuruFocus.com

5 months ago

Repligen Stock Soars 10% on Record Growth and Bold Moves

MT Newswires

5 months ago

Sector Update: Health Care Stocks Mixed Premarket Tuesday

Repligen (RGEN) Q3 Earnings and Revenues Beat Estimates

Zacks

5 months ago

Repligen (RGEN) Q3 Earnings and Revenues Beat Estimates

MT Newswires

5 months ago

Sector Update: Health Care

MT Newswires

5 months ago

Repligen Q3 Adjusted Earnings, Revenue Rise; 2024 Guidance Updated

Associated Press Finance

5 months ago

Repligen: Q3 Earnings Snapshot

Repligen Reports Third Quarter 2024 Financial Results

GlobeNewswire

5 months ago

Repligen Reports Third Quarter 2024 Financial Results

Repligen Corp (RGEN) Q3 2024: Everything You Need to Know Ahead of Earnings

GuruFocus.com

5 months ago

Repligen Corp (RGEN) Q3 2024: Everything You Need to Know Ahead of Earnings

Argus Research

6 months ago

RGEN: Raising target price to $121.00

Repligen Corporation to Present at Upcoming Investor Conferences

GlobeNewswire

6 months ago

Repligen Corporation to Present at Upcoming Investor Conferences

Share on Social Networks: